NCT00644878 - Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Interventions

DRUG

Nilotinib

Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.

Trial Locations (11)

21229

St. Agnes Hospital, Baltimore

29615

Cancer Centers of the Carolinas, Greenville

30912

Georgia Health Sciences University Dept. of MCG, Augusta

46107

Indiana Blood and Marrow Institute, Beech Grove

52242

University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic, Iowa City

53226

Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial, Milwaukee

70115

LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans

77030

Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr, Houston

78405

South Texas Institute of Cancer, Corpus Christi

84604

Central Utah Clinic Central Utah Clinic (7), Provo

90033

USC Norris Cancer Center Jane Anne Nohl, Los Angeles